Haploidentical transplantation in primary refractory/relapsed secondary vs de novo AML: from the ALWP/EBMT

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F24%3A00013689" target="_blank" >RIV/00023736:_____/24:00013689 - isvavai.cz</a>

Výsledek na webu

<a href="https://doi.org/10.1182/bloodadvances.2024012798" target="_blank" >https://doi.org/10.1182/bloodadvances.2024012798</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1182/bloodadvances.2024012798" target="_blank" >10.1182/bloodadvances.2024012798</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Haploidentical transplantation in primary refractory/relapsed secondary vs de novo AML: from the ALWP/EBMT

Popis výsledku v původním jazyce

We compared the outcomes of haploidentical stem cell transplantation (haplo-HSCT) with posttransplant cyclophosphamide (PTCy) in 719 patients with primary refractory (PR) or first relapse (Rel) secondary acute myeloid leukemia (sAML, n = 129) vs those with de novo AML (n = 590), who received HSCT between 2010 and 2022. A higher percentage of patients with sAML vs de novo AML had PR disease (73.6% vs 58.6%, P = .002). In 81.4% of patients with sAML, the antecedent hematological disorder was myelodysplastic syndrome. Engraftment was 83.5% vs 88.4% in sAML and de novo AML, respectively (P = .13). In multivariate analysis, haplo-HSCT outcomes did not differ significantly between the groups: nonrelapse mortality hazard ratio (HR), 1.38 (95% confidence interval [CI], 0.96-1.98, P = .083), relapse incidence HR, 0.68 (95% CI, 0.4.7.-1.00, P = .051). The HRs for leukemia-free survival, overall survival, and graft-versus-host disease (GVHD)-free, and GVHD and relapse-free survival were 0.99 (95% CI, 0.76-1.28, P = .94), 0.99 (95% CI, 0.77-1.29, P = .97), and 0.99 (95% CI, 0.77-1.27, P = .94), respectively. We conclude that outcomes of haplo-HSCT with PTCy are not different for PR/Rel sAML in comparison with PR/Rel de novo AML, a finding of major clinical importance.

Název v anglickém jazyce

Haploidentical transplantation in primary refractory/relapsed secondary vs de novo AML: from the ALWP/EBMT

Popis výsledku anglicky

We compared the outcomes of haploidentical stem cell transplantation (haplo-HSCT) with posttransplant cyclophosphamide (PTCy) in 719 patients with primary refractory (PR) or first relapse (Rel) secondary acute myeloid leukemia (sAML, n = 129) vs those with de novo AML (n = 590), who received HSCT between 2010 and 2022. A higher percentage of patients with sAML vs de novo AML had PR disease (73.6% vs 58.6%, P = .002). In 81.4% of patients with sAML, the antecedent hematological disorder was myelodysplastic syndrome. Engraftment was 83.5% vs 88.4% in sAML and de novo AML, respectively (P = .13). In multivariate analysis, haplo-HSCT outcomes did not differ significantly between the groups: nonrelapse mortality hazard ratio (HR), 1.38 (95% confidence interval [CI], 0.96-1.98, P = .083), relapse incidence HR, 0.68 (95% CI, 0.4.7.-1.00, P = .051). The HRs for leukemia-free survival, overall survival, and graft-versus-host disease (GVHD)-free, and GVHD and relapse-free survival were 0.99 (95% CI, 0.76-1.28, P = .94), 0.99 (95% CI, 0.77-1.29, P = .97), and 0.99 (95% CI, 0.77-1.27, P = .94), respectively. We conclude that outcomes of haplo-HSCT with PTCy are not different for PR/Rel sAML in comparison with PR/Rel de novo AML, a finding of major clinical importance.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Blood advances

ISSN

2473-9529

e-ISSN

—

Svazek periodika

8

Číslo periodika v rámci svazku

15.

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

11

Strana od-do

4223-4233

Kód UT WoS článku

001296452000001

EID výsledku v databázi Scopus

2-s2.0-85201506819